

Protecting the World's Vision

Shigeo Taniuchi President & COO Santen Pharmaceutical Co., Ltd.

J.P. Morgan Healthcare Conference January 7, 2019



Disclosure Notice



- Information given in presentation contains certain forward-looking statements concerning forecasts, projections and plans whose realization is subject to risk and uncertainty from a variety of sources. Actual results may differ significantly from forecasts.
- Business performance and financial condition are subject to the effects of medical regulatory changes made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates.
- The process of drug research and development from discovery to final approval and sales is long, complex and uncertain. Individual
 compounds are subject to a multitude of uncertainties, including the termination of clinical development at various stages and the nonapproval of products after a regulatory filing has been submitted. Forecasts and projections concerning new products take into account
 assumptions concerning the development pipelines of other companies and any co-promotion agreements, existing or planned. The success
 or failure of such agreements could affect business performance and financial condition significantly.
- Business performance and financial conditions could be affected significantly by a substantial drop in sales of a major drug, either currently
 marketed or expected to be launched, due to termination of sales as a result of factors such as patent expiry and complications, product
 defects or unforeseen side effects. Santen Pharmaceutical also sells numerous products under sales and/or manufacturing license from other
 companies. Business performance could be affected significantly by changes in the terms and conditions of agreements and/or the nonrenewal of agreements.
- Santen Pharmaceutical is reliant on specific companies for supplies of certain raw materials used in production. Business performance could be affected significantly by the suspension or termination of supplies of such raw materials if such and event were to adversely affect supply capabilities for related final products.
- This presentation includes discussions of certain Santen products marketed in certain markets and compounds in clinical trials, as well as competitors and their products and compounds in clinical trials which are given for illustrative purposes only. Such discussions may include views subject to data interpretation that may or may not be views shared by regulatory authorities in the various regions in which the Company operates.

Santen Overall

- Specialized in ophthalmology since 1890



Santen's Values and Mission Statement



機に参与す Tenki ni sanyo suru¹

Values

¹ "Exploring the secrets and mechanisms of nature in order to contribute to people's health"


Santen's original interpretation of a passage from chapter 22 of Zhongyong (The Doctrine of the Mean) by Confucius.

We think carefully about what is essential, decide clearly what we should do, and act quickly.

Mission Statement

By focusing on ophthalmology, Santen develops unique scientific knowledge and organizational capabilities that contribute to the well-being of patients, their loved ones and consequently to society.

Our Contributions to Better Serve Patients in Ophthalmology




Eylea: Co-promoted product of Bayer Yakuhin, Ltd. (MAH)

Santen

Continuous Growth and Expansion Globally While Contributing to Ophthalmology









Answering the Needs in Each Region






Broad Product Lineup Covering All Disease Areas



Santen

Product Development to Satisfy Wide Ranging Needs





Efficient Product Development






Capturing Growth Opportunities



Ophthalmic Industry: Needs and Direction







Allergic blepharoconjunctivitis



Purulent endophthalmitis (secondary to infection



nitis Cataract




Glaucoma patient view at end-stage



Age-related macular degeneration patient view







*Asia 18 countries/areas (excluding Japan)


*Asia Market Scale

: Based on IQVIA MIDAS 2015 excluding S01S, L, Korea OTC and China retail/ 10 countries + India. Copyright © 2019 IQVIA. Reprinted with permission. FY2020, FY2030: Santen estimates.



Santen's Business Expansion in Asia






Copyright© 2019 Santen Pharmaceutical Co., Ltd. All rights reserved






Global Glaucoma Patient Population




Sources: Market Scope, Br J Ophthalmol. 2006 Mar; 90(3): 262–267., Santen estimates

U.S. Demand for Minimally-Invasive Glaucoma Surgery (MIGS)




Santen's Glaucoma Portfolio

-Positioning to Address All Stages of Glaucoma





Santen's Latest Work in the Glaucoma Treatment Area Santen



Santen's Sustainable Growth into the Future

- To become a "Specialized pharmaceutical Company with a Global Presence"




Vision 2020: Long-Term Vision Based on Santen's Values



Santen


Steady Earnings Growth with **Ophthalmology Specialization**







Steady Earnings Growth with Ophthalmology Specialization












Start North America Business with Differentiated Products






Pipeline Launch Targets



As of January 7, 2019



Protecting the World's Vision



Continuous Journey to Maximize the Joy of Vision All Over the World



Always Pursuing Further Contribution to Ophthalmology

as a Unique and Specialized Presence in the Field



